← Back to Screener
Scilex Holding Company Common Stock (SCLX)
Price$6.59
Favorite Metrics
Price vs S&P 500 (26W)-68.15%
Price vs S&P 500 (4W)-24.22%
Market Capitalization$53.49M
All Metrics
P/CF (Annual)14.02x
Book Value / Share (Quarterly)$0.07
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-7.34%
Cash Flow / Share (Quarterly)$-4.51
Price vs S&P 500 (YTD)-51.00%
Gross Margin (TTM)64.97%
Net Profit Margin (TTM)-1185.78%
EPS (TTM)$-31.60
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-31.60
Revenue Growth (5Y)5.13%
EPS (Annual)$-32.51
ROI (Annual)-64.46%
Gross Margin (Annual)64.97%
Net Profit Margin (5Y Avg)-380.55%
Cash / Share (Quarterly)$1.56
Revenue Growth QoQ (YoY)-67.83%
ROA (Last FY)-98.29%
Revenue Growth TTM (YoY)-46.54%
EBITD / Share (TTM)$-31.65
Operating Margin (TTM)-1168.01%
Cash Flow / Share (Annual)$-1.84
P/B Ratio5.09x
P/B Ratio (Quarterly)78.88x
Net Income / Employee (Annual)$-12
EV / Revenue (TTM)5.49x
Net Interest Coverage (TTM)-17.27x
ROA (TTM)-178.57%
EPS Incl Extra (Annual)$-32.51
Current Ratio (Annual)0.08x
Quick Ratio (Quarterly)0.05x
3-Month Avg Trading Volume0.06M
52-Week Price Return-4.83%
EV / Free Cash Flow (Annual)6.16x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-2.27
P/S Ratio (Annual)1.77x
Asset Turnover (Annual)0.08x
52-Week High$34.27
Operating Margin (5Y Avg)-350.60%
EPS Excl Extra (Annual)$-32.51
CapEx CAGR (5Y)254.39%
26-Week Price Return-64.16%
Quick Ratio (Annual)0.05x
13-Week Price Return-52.99%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.08x
Enterprise Value$166.199
Revenue / Share Growth (5Y)75.07%
Asset Turnover (TTM)0.15x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.93x
Pretax Margin (Annual)-1236.33%
Cash / Share (Annual)$1.56
3-Month Return Std Dev75.72%
Gross Margin (5Y Avg)72.39%
Net Income / Employee (TTM)$-12
ROE (Last FY)-64.46%
Net Interest Coverage (Annual)-2.22x
EPS Basic Excl Extra (Annual)$-32.51
P/FCF (TTM)3.08x
Receivables Turnover (TTM)1.45x
EV / Free Cash Flow (TTM)27.02x
Total Debt / Equity (Quarterly)3.31x
EPS Incl Extra (TTM)$-31.60
Receivables Turnover (Annual)1.45x
P/S Ratio (TTM)1.77x
Pretax Margin (5Y Avg)-390.66%
Revenue / Share (Annual)$2.74
Tangible BV / Share (Annual)$-0.13
Forward P/E2.64x
Price vs S&P 500 (52W)-34.66%
Year-to-Date Return-48.36%
5-Day Price Return-10.13%
EPS Normalized (Annual)$-32.51
ROA (5Y Avg)-85.99%
Net Profit Margin (Annual)-1185.78%
Month-to-Date Return-5.41%
Cash Flow / Share (TTM)$-1.13
EBITD / Share (Annual)$-31.65
Operating Margin (Annual)-1168.01%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)11.26x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-31.60
P/B Ratio (Annual)15.56x
Inventory Turnover (TTM)2.93x
Pretax Margin (TTM)-1236.33%
Book Value / Share (Annual)$0.26
Price vs S&P 500 (13W)-53.67%
Beta1.34x
P/FCF (Annual)2.85x
Revenue / Share (TTM)$3.23
ROE (TTM)-130.91%
52-Week Low$3.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SCLXScilex Holding Company Common Stock | 1.77x | -46.54% | 64.97% | — | $6.59 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Scilex Holding Co develops non-opioid pain management therapeutics for acute and chronic pain conditions. Commercial products include ZTlido (lidocaine topical system for postherpetic neuralgia) and Gloperba (colchicine oral solution for gout flare prevention). The clinical pipeline comprises SP-102 (corticosteroid gel for epidural injection), SP-103 (enhanced lidocaine formulation), and SP-104 (low-dose naltrexone capsule).